Effect of Anti-inflammatory Treatment on Depression, Effects

JAMA Psychiatry

71, 1381

DOI: 10.1001/jamapsychiatry.2014.1611

Citation Report

#	Article	IF	Citations
1	Psychodermatology in Clinical Practice: Main Principles. Acta Dermato-Venereologica, 2014, 96, 30-4.	0.6	8
2	Cytokine variations and mood disorders: influence of social stressors and social support. Frontiers in Neuroscience, 2014, 8, 416.	1.4	41
3	Depression and the risk of autoimmune disease: a nationally representative, prospective longitudinal study. Psychological Medicine, 2015, 45, 3559-3569.	2.7	75
4	Lâ€™histoire de la science du stressÂ: de Hans Selye Ã la dÃ©couverte des anti-inflammatoires. Sante Mentale Au Quebec, 0, 40, 275-286.	0.1	8
5	Cross-talk between systemic and cerebral inflammation in depressive disorders: Relevance to pathogenesis and treatment. Psychiatry and Clinical Neurosciences, 2015, 69, 506-507.	1.0	2
6	Behavioral Symptoms after Breast Cancer Treatment: A Biobehavioral Approach. Journal of Personalized Medicine, 2015, 5, 280-295.	1.1	30
7	Depression and diabetes: treatment and health-care delivery. Lancet Diabetes and Endocrinology,the, 2015, 3, 472-485.	5.5	156
8	The effect of the antipsychotic drug quetiapine and its metabolite norquetiapine on acute inflammation, memory and anhedonia. Pharmacology Biochemistry and Behavior, 2015, 135, 136-144.	1.3	29
9	Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes. Brain and Behavior, 2015, 5, e00338.	1.0	55
10	Sick and Tired: Mood, Fatigue, and Inflammation in Cancer. Current Psychiatry Reports, 2015, 17, 555.	2.1	11
11	Plasma levels of soluble TNF receptors 1 and 2 after tDCS and sertraline treatment in major depression: Results from the SELECT-TDCS trial. Journal of Affective Disorders, 2015, 185, 209-213.	2.0	24
12	Cumulative meta-analysis of interleukins 6 and 1Î², tumour necrosis factor Î± and C-reactive protein in patients with major depressive disorder. Brain, Behavior, and Immunity, 2015, 49, 206-215.	2.0	830
13	Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Molecular Psychiatry, 2015, 20, 1142-1150.	4.1	100
14	Examining the role of neuroinflammation in major depression. Psychiatry Research, 2015, 229, 27-36.	1.7	160
15	Psychopharmacological Strategies in the Management of Posttraumatic Stress Disorder (PTSD): What Have We Learned?. Current Psychiatry Reports, 2015, 17, 564.	2.1	68
16	C-Reactive Protein: A Stress Diathesis Marker at the Crossroads of Maladaptive Behavioral and Cardiometabolic Sequelae. American Journal of Psychiatry, 2015, 172, 307-309.	4.0	16
17	Are Anti-inflammatory Therapies Viable Treatments for Psychiatric Disorders?. JAMA Psychiatry, 2015, 72, 527.	6.0	87
18	Anti-inflammatory Intervention in Depression. JAMA Psychiatry, 2015, 72, 511.	6.0	9

#	Article	IF	Citations
19	Anti-inflammatory Intervention in Depression. JAMA Psychiatry, 2015, 72, 511.	6.0	2
20	Pre-treatment effects of peripheral tumors on brain and behavior: Neuroinflammatory mechanisms in humans and rodents. Brain, Behavior, and Immunity, 2015, 49, 1-17.	2.0	42
21	Anti-inflammatory Intervention in Depression. JAMA Psychiatry, 2015, 72, 512.	6.0	2
22	Are medical comorbid conditions of bipolar disorder due to immune dysfunction?. Acta Psychiatrica Scandinavica, 2015, 132, 180-191.	2.2	84
23	Neuroimmune mechanisms of depression. Nature Neuroscience, 2015, 18, 1386-1393.	7.1	415
24	Kynurenine pathway (KP) inhibitors: Novel agents for the management of depression. Journal of Psychopharmacology, 2015, 29, 1133-1134.	2.0	5
25	Depression as a Microglial Disease. Trends in Neurosciences, 2015, 38, 637-658.	4.2	642
26	Interferon-alpha treatment induces depression-like behaviour accompanied by elevated hippocampal quinolinic acid levels in rats. Behavioural Brain Research, 2015, 293, 166-172.	1.2	41
27	Elevated body temperature is linked to fatigue in an Italian sample of relapsingâ€“remitting multiple sclerosis patients. Journal of Neurology, 2015, 262, 2440-2442.	1.8	22
28	Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders. Psychiatry Research, 2015, 229, 37-48.	1.7	145
29	Five potential therapeutic agents as antidepressants: a brief review and future directions. Expert Review of Neurotherapeutics, 2015, 15, 1015-1029.	1.4	8
30	Inflammation: Depression Fans the Flames and Feasts on the Heat. American Journal of Psychiatry, 2015, 172, 1075-1091.	4.0	544
31	Anti-inflammatory Intervention in Depressionâ€”Reply. JAMA Psychiatry, 2015, 72, 512.	6.0	8
32	Implementing Treatment Strategies for Different Types of Depression. Journal of Clinical Psychiatry, 2016, 77, 9-15.	1.1	7
33	Patients with depression display cytokine levels in serum and cerebrospinal fluid similar to patients with diffuse neurological symptoms without a defined diagnosis. Neuropsychiatric Disease and Treatment, 2016, 12, 817.	1.0	28
34	EGb761 attenuates depressive-like behaviours induced by long-term light deprivation in C57BL/6J mice through inhibition of NF-ÎºB-IL-6 signalling pathway. Central-European Journal of Immunology, 2016, 4, 350-357.	0.4	4
35	Inflammation in Depression and the Potential for Anti-Inflammatory Treatment. Current Neuropharmacology, 2016, 14, 732-742.	1.4	367
36	Minocycline and celecoxib as adjunctive treatments for bipolar depression: a study protocol for a multicenter factorial design randomized controlled trial. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 1-8.	1.0	23

#	Article	IF	Citations
37	Nitric Oxide and Major Depressive Disorder: Pathophysiology and Treatment Implications. Current Molecular Medicine, 2016, 16, 206-215.	0.6	46
38	Neuroimmune Interface in the Comorbidity between Alcohol Use Disorder and Major Depression. Frontiers in Immunology, 2016, 7, 655.	2.2	53
39	Effects of Group Drumming Interventions on Anxiety, Depression, Social Resilience and Inflammatory Immune Response among Mental Health Service Users. PLoS ONE, 2016, 11, e0151136.	1.1	89
40	The Predictive Value of Depressive Symptoms for All-Cause Mortality. Psychosomatic Medicine, 2016, 78, 401-411.	1.3	17
41	Autoimmune diseases can be associated with depression. Evidence-Based Mental Health, 2016, 19, e27-e27.	2.2	3
42	Protective effect of liquiritigenin on depressive-like behavior in mice after lipopolysaccharide administration. Psychiatry Research, 2016, 240, 131-136.	1.7	17
43	Antidepressant therapies inhibit inflammation and microglial M1-polarization. , 2016, 163, 82-93.		167
44	Deconstructing Diabetes and Depression: Clinical Context, Treatment Strategies, and New Directions. Focus (American Psychiatric Publishing), 2016, 14, 184-193.	0.4	3
45	The Effect of Concomitant Treatment With SSRIs and Statins: A Population-Based Study. American Journal of Psychiatry, 2016, 173, 807-815.	4.0	63
46	Celecoxib attenuates depressive-like behavior associated with immunological liver injury in C57BL/6 mice through TNF-Î± and NF-Îºb dependent mechanisms. Life Sciences, 2016, 163, 23-37.	2.0	17
47	Examining the relationship between physical illness and depression: Is there a difference between inflammatory and non inflammatory diseases? A cohort study. General Hospital Psychiatry, 2016, 43, 71-77.	1.2	17
48	Major depressive disorder. Nature Reviews Disease Primers, 2016, 2, 16065.	18.1	1,171
49	Metabolic-Inflammation Aspects of Depression and Cardiovascular Disease. , 2016, , 211-233.		0
50	Genetic Overlap Between Depression and Cardiometabolic Disorders. , 2016, , 235-255.		0
51	Anti-inflammatory Agents for the Treatment of Depression in the Light of Comorbid Cardiovascular Disease. , 2016, , 445-465.		0
52	Pharmacological Treatment and Prevention of Cardiovascular Diseases and Depression Comorbidity: Understanding Epidemiological, Clinical Trial Evidence, and the Biological Underpinnings. , 2016, , 411-443.		0
53	Immune signatures and disorder-specific patterns in a cross-disorder gene expression analysis. British Journal of Psychiatry, 2016, 209, 202-208.	1.7	31
54	Serum proteomic profiles of depressive subtypes. Translational Psychiatry, 2016, 6, e851-e851.	2.4	56

#	Article	IF	Citations
55	The mechanism of 5-lipoxygenase in the impairment of learning and memory in rats subjected to chronic unpredictable mild stress. Physiology and Behavior, 2016, 167, 145-153.	1.0	25
56	Treatment of depression with low-strength transcranial pulsed electromagnetic fields: A mechanistic point of view. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 71, 137-143.	2.5	16
57	Antinociceptive and Antiâ€inflammatory Effects of Ketamine and the Relationship to Its Antidepressant Action and GSK3 Inhibition. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 562-573.	1.2	16
58	Circulating biosignatures of late-life depression (LLD): Towards a comprehensive, data-driven approach to understanding LLD pathophysiology. Journal of Psychiatric Research, 2016, 82, 1-7.	1.5	41
59	The Microbiota, Immunoregulation, and Mental Health: Implications for Public Health. Current Environmental Health Reports, 2016, 3, 270-286.	3.2	150
60	The Immune System and the Role of Inflammation in Perinatal Depression. Neuroscience Bulletin, 2016, 32, 398-420.	1.5	95
61	Are Non-steroidal Anti-Inflammatory Drugs Clinically Suitable for the Treatment of Symptoms in Depression-Associated Inflammation?. Current Topics in Behavioral Neurosciences, 2016, 31, 303-319.	0.8	33
62	Inflammation Effects on Brain Glutamate in Depression: Mechanistic Considerations and Treatment Implications. Current Topics in Behavioral Neurosciences, 2016, 31, 173-198.	0.8	99
63	The Microbiomeâ€“Gutâ€“Brain Axis and the Consequences of Infection and Dysbiosis. American Journal of Gastroenterology Supplements (Print), 2016, 3, 33-40.	0.7	3
64	Circadian preferences, oxidative stress and inflammatory cytokines in bipolar disorder: A community study. Journal of Neuroimmunology, 2016, 301, 23-29.	1.1	27
65	Side effect profile similarities shared between antidepressants and immune-modulators reveal potential novel targets for treating major depressive disorders. BMC Pharmacology & Toxicology, 2016, 17, 47.	1.0	7
66	The Promise and Limitations of Anti-Inflammatory Agents for the Treatment of Major Depressive Disorder. Current Topics in Behavioral Neurosciences, 2016, 31, 287-302.	0.8	24
67	Inflammation and the Silent Sequelae of Stroke. Neurotherapeutics, 2016, 13, 801-810.	2.1	37
68	Antiâ€inflammatory agents in the treatment of bipolar depression: a systematic review and metaâ€analysis. Bipolar Disorders, 2016, 18, 89-101.	1.1	153
69	Pathogenesis of depression: Insights from human and rodent studies. Neuroscience, 2016, 321, 138-162.	1.1	383
70	Novel approaches for the management of depressive disorders. European Journal of Pharmacology, 2016, 771, 236-240.	1.7	35
71	Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1944-52.	3.3	123
72	Concomitant NSAID use during antipsychotic treatment and risk of 2-year relapse â€“ a population-based study of 16,253 incident patients with schizophrenia. Expert Opinion on Pharmacotherapy, 2016, 17, 1055-1062.	0.9	11

#	Article	IF	Citations
73	Mapping inflammation onto mood: Inflammatory mediators of anhedonia. Neuroscience and Biobehavioral Reviews, 2016, 64, 148-166.	2.9	97
74	A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Molecular Psychiatry, 2016, 21, 1696-1709.	4.1	1,197
75	Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders. , 2016, , .		3
76	Associations of low grade inflammation and endothelial dysfunction with depression â€“ The Maastricht Study. Brain, Behavior, and Immunity, 2016, 56, 390-396.	2.0	103
77	Depression and the risk of severe infections: prospective analyses on a nationwide representative sample. International Journal of Epidemiology, 2016, 45, 131-139.	0.9	83
78	The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nature Reviews Immunology, 2016, 16, 22-34.	10.6	2,350
79	Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans. Brain, Behavior, and Immunity, 2016, 51, 29-38.	2.0	42
80	Microglial dysfunction connects depression and Alzheimerâ€™s disease. Brain, Behavior, and Immunity, 2016, 55, 151-165.	2.0	100
81	Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?. Psychopharmacology, 2016, 233, 1591-1604.	1.5	52
82	Alterations in functional connectivity of resting state networks during experimental endotoxemia â€“ An exploratory study in healthy men. Brain, Behavior, and Immunity, 2016, 54, 17-26.	2.0	71
83	Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?. Psychopharmacology, 2016, 233, 1575-1589.	1.5	146
84	Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Molecular Psychiatry, 2016, 21, 71-79.	4.1	217
85	Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research. Molecular Neurobiology, 2016, 53, 2927-2935.	1.9	40
86	Depressive-like behavior, its sensitization, social buffering, and altered cytokine responses in rhesus macaques moved from outdoor social groups to indoor housing. Social Neuroscience, 2017, 12, 65-75.	0.7	31
87	Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience. Neuropsychopharmacology, 2017, 42, 62-80.	2.8	241
88	White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2017, 51, 355-365.	1.3	22
89	Advanced Glycation End Product (AGE) Accumulation in the Skin is Associated with Depression: The Maastricht Study. Depression and Anxiety, 2017, 34, 59-67.	2.0	32
90	Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Review of Neurotherapeutics, 2017, 17, 593-609.	1.4	65

#	Article	IF	Citations
91	Associations between inflammation-related biomarkers and depressive symptoms in individuals with recently diagnosed type 1 and type 2 diabetes. Brain, Behavior, and Immunity, 2017, 61, 137-145.	2.0	24
92	Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder. Depression and Anxiety, 2017, 34, 281-290.	2.0	12
93	Early onset of inflammation during ontogeny of bipolar disorder: the NLRP2 inflammasome gene distinctly differentiates between patients and healthy controls in the transition between iPS cell and neural stem cell stages. Translational Psychiatry, 2017, 7, e1010-e1010.	2.4	38
94	Behavioural Effects of Using Sulfasalazine to Inhibit Glutamate Released by Cancer Cells: A Novel target for Cancer-Induced Depression. Scientific Reports, 2017, 7, 41382.	1.6	19
95	IL-6 and TNF-Î± in unmedicated adults with ADHD: Relationship to cortisol awakening response. Psychoneuroendocrinology, 2017, 79, 67-73.	1.3	32
96	Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: Case-controlled study. Brain, Behavior, and Immunity, 2017, 62, 212-218.	2.0	132
97	Inflammatory cytokines and functional impairment in drug-free subjects with mood disorder. Journal of Neuroimmunology, 2017, 307, 33-36.	1.1	19
98	Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. Brain, Behavior, and Immunity, 2017, 62, 344-350.	2.0	202
99	Microglia Loss Contributes to the Development of Major Depression Induced by Different Types of Chronic Stresses. Neurochemical Research, 2017, 42, 2698-2711.	1.6	81
100	Immunopsychiatry: important facts. Psychological Medicine, 2017, 47, 2229-2237.	2.7	117
101	Dilated Virchowâ€“Robin spaces in the hippocampus impact behaviors and effects of anti-depressant treatment in model of depressed rats. Journal of Affective Disorders, 2017, 219, 17-24.	2.0	11
102	Prefrontal cortical glutathione-dependent defense and proinflammatory mediators in chronically isolated rats: Modulation by fluoxetine or clozapine. Neuroscience, 2017, 355, 49-60.	1.1	14
103	The influence of stress on neuroinflammation and alterations in brain structure and function in major depressive disorder. Behavioural Brain Research, 2017, 329, 6-11.	1.2	125
104	Considering future pharmacotherapy for PTSD. Neuroscience Letters, 2017, 649, 181-185.	1.0	51
105	Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: A randomized double-blind, placebo controlled trial. Psychiatry Research, 2017, 255, 59-65.	1.7	35
106	Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial. Australian and New Zealand Journal of Psychiatry, 2017, 51, 829-840.	1.3	75
107	Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Translational Psychiatry, 2017, 7, e1065-e1065.	2.4	135
108	Relative to SSRI users, SSRIâ€“statin users have fewer psychiatric hospital contacts and no increase in suicidal behaviour or all-cause mortality. Evidence-Based Mental Health, 2017, 20, 60-60.	2.2	2

#	Article	IF	Citations
109	Association between psychological measures with inflammatory anddisease-related markers of inflammatory bowel disease. International Journal of Psychiatry in Clinical Practice, 2017, 21, 221-230.	1.2	28
110	The Inflammatory Potential of the Diet Is Associated with Depressive Symptoms in Different Subgroups of the General Population. Journal of Nutrition, 2017, 147, 879-887.	1.3	60
111	Do Statins Have Antidepressant Effects?. CNS Drugs, 2017, 31, 335-343.	2.7	22
112	Monoclonal antibody immunotherapy in psychiatric disorders. Lancet Psychiatry,the, 2017, 4, 13-15.	3.7	16
113	The microbiome, immunity, and schizophrenia and bipolar disorder. Brain, Behavior, and Immunity, 2017, 62, 46-52.	2.0	209
114	Depression as a systemic disease. Personalized Medicine in Psychiatry, 2017, 1-2, 11-25.	0.1	25
115	Inflammation-Associated Depression: Evidence, Mechanisms and Implications. Current Topics in Behavioral Neurosciences, 2017, , .	0.8	24
116	PPAR-Î³ Agonists for the Treatment of Major Depression: A Review. Pharmacopsychiatry, 2017, 50, 49-55.	1.7	67
117	Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic Dysregulations. JAMA Psychiatry, 2017, 74, 1214.	6.0	174
118	Depression in the Context of Medical Disorders: New Pharmacological Pathways Revisited. NeuroSignals, 2017, 25, 54-73.	0.5	5
119	Backing into the future: pharmacological approaches to the management of resistant depression. Psychological Medicine, 2017, 47, 2569-2577.	2.7	29
120	Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis. Journal of Psychopharmacology, 2017, 31, 1137-1148.	2.0	97
121	Drug repurposing may generate novel approaches to treating depression. Journal of Pharmacy and Pharmacology, 2017, 69, 1428-1436.	1.2	25
122	Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders. Neuroscience and Biobehavioral Reviews, 2017, 80, 555-572.	2.9	31
123	Microbiome, inflammation, epigenetic alterations, and mental diseases. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 651-660.	1.1	165
124	No Impact of Preadmission Anti-Inflammatory Drug Use on Risk of Depression and Anxiety After Critical Illness*. Critical Care Medicine, 2017, 45, 1635-1641.	0.4	6
125	The role of anxious distress in immune dysregulation in patients with major depressive disorder. Translational Psychiatry, 2017, 7, 1268.	2.4	47
126	Effects of Shambhavi Mahamudra Kriya, a Multicomponent Breath-Based Yogic Practice (Pranayama), on Perceived Stress and General Well-Being. Journal of Evidence-Based Complementary & Alternative Medicine, 2017, 22, 788-797.	1.5	37

#	Article	IF	Citations
127	From Homeostasis to Allodynamic Regulation. , 0, , 401-426.		3
128	Positive association between Toxoplasma gondii IgG serointensity and current dysphoria/hopelessness scores in the Old Order Amish: a preliminary study. Pteridines, 2017, 28, 185-194.	0.5	8
129	White blood cell count at first depression diagnosis as predictor for risk of subsequent hospitalization with depression. Neurology Psychiatry and Brain Research, 2017, 26, 1-6.	2.0	5
130	Neurobiology of Chronic Stress-Related Psychiatric Disorders: Evidence from Molecular Imaging Studies. Chronic Stress, 2017, 1, 247054701771091.	1.7	63
131	The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castlemanâ€™s disease. Brain, Behavior, and Immunity, 2017, 66, 156-164.	2.0	69
132	Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. Journal of Psychopharmacology, 2017, 31, 1149-1165.	2.0	191
133	How to: Measuring blood cytokines in biological psychiatry using commercially available multiplex immunoassays. Psychoneuroendocrinology, 2017, 75, 72-82.	1.3	38
134	Improvement of psychiatric symptoms in youth following resolution of sinusitis. International Journal of Pediatric Otorhinolaryngology, 2017, 92, 38-44.	0.4	9
135	Depression in cancer: The many biobehavioral pathways driving tumor progression. Cancer Treatment Reviews, 2017, 52, 58-70.	3.4	204
136	Inflammation Effects on Motivation and Motor Activity: Role of Dopamine. Neuropsychopharmacology, 2017, 42, 216-241.	2.8	272
137	Therapeutic Implications of Brainâ€“Immune Interactions: Treatment in Translation. Neuropsychopharmacology, 2017, 42, 334-359.	2.8	113
138	Hidden Wounds? Inflammatory Links Between Childhood Trauma and Psychopathology. Annual Review of Psychology, 2017, 68, 517-544.	9.9	190
139	Why are behavioral and immune traits linked?. Hormones and Behavior, 2017, 88, 52-59.	1.0	36
140	Proteomic investigation of the prefrontal cortex in the rat clomipramine model of depression. Journal of Proteomics, 2017, 153, 53-64.	1.2	21
141	Psychoneuroimmunology of Early-Life Stress: The Hidden Wounds of Childhood Trauma?. Neuropsychopharmacology, 2017, 42, 99-114.	2.8	259
142	New medications for treatment-resistant depression: a brief review of recent developments. CNS Spectrums, 2017, 22, 39-48.	0.7	11
143	Association between pro- and anti-inflammatory cytokines and depressive symptoms in patients with diabetesâ€”potential differences by diabetes type and depression scores. Translational Psychiatry, 2017, 7, 1.	2.4	75
144	Biomarkers for depression: recent insights, current challenges and future prospects. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 1245-1262.	1.0	242

#	Article	IF	Citations
145	Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications. Brain Sciences, 2017, 7, 144.	1.1	162
146	Neuroimmune Interactions in Schizophrenia: Focus on Vagus Nerve Stimulation and Activation of the Alpha-7 Nicotinic Acetylcholine Receptor. Frontiers in Immunology, 2017, 8, 618.	2.2	41
147	Visceral Inflammation and Immune Activation Stress the Brain. Frontiers in Immunology, 2017, 8, 1613.	2.2	50
148	A bidirectional relationship between depression and the autoimmune disorders â€“ New perspectives from the National Child Development Study. PLoS ONE, 2017, 12, e0173015.	1.1	76
149	The reninâ€“angiotensin system: a possible new target for depression. BMC Medicine, 2017, 15, 144.	2.3	98
150	ANTI-ULCEROGENIC EFFICACY AND MECHANISMS OF EDIBLE AND NATURAL INGREDIENTS IN NSAID-INDUCED ANIMAL MODELS. Tropical Journal of Obstetrics and Gynaecology, 2017, 14, 221-238.	0.3	4
151	Anti-inflammatory treatment and risk for depression. Journal of Psychiatry and Neuroscience, 2017, 42, 320-330.	1.4	29
152	Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. Journal of Affective Disorders, 2018, 232, 127-133.	2.0	46
153	Prevalence and correlates of low-grade systemic inflammation in adult psychiatric inpatients: An electronic health record-based study. Psychoneuroendocrinology, 2018, 91, 226-234.	1.3	75
154	Neither all anti-inflammatory drugs nor all doses are effective in accelerating the antidepressant-like effect of fluoxetine in an animal model of depression. Journal of Affective Disorders, 2018, 235, 124-128.	2.0	10
155	Neuroimmune Biomarkers in Mental Illness. Current Topics in Behavioral Neurosciences, 2018, 40, 45-78.	0.8	27
156	Inflammatory cytokines and depression in children with cancer: A review of the literature. Pediatric Hematology and Oncology, 2018, 35, 11-19.	0.3	2
157	Granulocyte-colony stimulating factor controls neural and behavioral plasticity in response to cocaine. Nature Communications, 2018, 9, 9.	5.8	213
158	Metabolic/inflammatory/vascular comorbidity in psychiatric disorders; soluble epoxide hydrolase (sEH) as a possible new target. Neuroscience and Biobehavioral Reviews, 2018, 87, 56-66.	2.9	54
159	Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2Ã—2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. Translational Psychiatry, 2018, 8, 27.	2.4	105
160	Association between virus exposure and depression in US adults. Psychiatry Research, 2018, 261, 73-79.	1.7	55
161	Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. Translational Psychiatry, 2018, 8, 10.	2.4	59
162	Drug repositioning: current approaches and their implications in the precision medicine era. Expert Review of Precision Medicine and Drug Development, 2018, 3, 49-61.	0.4	48

#	Article	IF	Citations
163	Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study. Neurotoxicity Research, 2018, 33, 621-633.	1.3	41
164	Interoception and Inflammation in Psychiatric Disorders. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 514-524.	1.1	61
165	Antidepressant Therapy for Depression: An Update. , 2018, , 241-255.		0
166	Modulating Microglial Activation As a Possible Therapeutic Target for Depression. , 2018, , 209-219.		0
167	Erythropoietin as an add-on treatment for cognitive side effects of electroconvulsive therapy: a study protocol for a randomized controlled trial. Trials, 2018, 19, 234.	0.7	7
168	Effects of opioid- and non-opioid analgesics on responses to psychosocial stress in humans. Hormones and Behavior, 2018, 102, 41-47.	1.0	75
170	Microglia Polarization and Endoplasmic Reticulum Stress in Chronic Social Defeat Stress Induced Depression Mouse. Neurochemical Research, 2018, 43, 985-994.	1.6	68
171	How Does Repetitive Transcranial Magnetic Stimulation Influence the Brain in Depressive Disorders?. Journal of ECT, 2018, 34, 79-86.	0.3	10
172	Psychoneuroimmunology of mental disorders. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2018, 11, 115-124.	0.2	2
173	Longitudinal associations between biomarkers of inflammation and changes in depressive symptoms in patients with type 1 and type 2 diabetes. Psychoneuroendocrinology, 2018, 91, 216-225.	1.3	22
174	Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Molecular Psychiatry, 2018, 23, 335-343.	4.1	452
175	Cytokine alterations and cognitive impairment in major depressive disorder: From putative mechanisms to novel treatment targets. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 177-188.	2.5	49
176	Depressive disorders: Processes leading to neurogeneration and potential novel treatments. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 189-204.	2.5	37
177	Effect of antidepressant treatment on peripheral inflammation markers â€“ A meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 217-226.	2.5	158
178	Gutâ€“brain actions underlying comorbid anxiety and depression associated with inflammatory bowel disease. Acta Neuropsychiatrica, 2018, 30, 275-296.	1.0	118
179	Sex differences in the neuro-immune consequences of stress: Focus on depression and anxiety. Brain, Behavior, and Immunity, 2018, 67, 1-12.	2.0	222
180	Future Directions in the Study of Early-Life Stress and Physical and Emotional Health: Implications of the Neuroimmune Network Hypothesis. Journal of Clinical Child and Adolescent Psychology, 2018, 47, 142-156.	2.2	62
181	Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons Between Schizophrenia, Bipolar Disorder, and Depression. Schizophrenia Bulletin, 2018, 44, 75-83.	2.3	262

#	Article	IF	Citations
182	Panax ginseng exerts antidepressant-like effects by suppressing neuroinflammatory response and upregulating nuclear factor erythroid 2 related factor 2 signaling in the amygdala. Journal of Ginseng Research, 2018, 42, 107-115.	3.0	37
183	Polyunsaturated fatty acids and inflammatory markers in major depressive episodes during pregnancy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 273-278.	2.5	30
184	Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials. Journal of Affective Disorders, 2018, 227, 219-225.	2.0	135
185	Depression subtyping based on evolutionary psychiatry: Proximate mechanisms and ultimate functions. Brain, Behavior, and Immunity, 2018, 69, 603-617.	2.0	84
186	Inflammatory Mediators in Mood Disorders: Therapeutic Opportunities. Annual Review of Pharmacology and Toxicology, 2018, 58, 411-428.	4.2	82
187	Peripheral proinflammatory cytokines in Chinese patients with generalised anxiety disorder. Journal of Affective Disorders, 2018, 225, 593-598.	2.0	48
188	Metabolic and inflammatory markers: associations with individual depressive symptoms. Psychological Medicine, 2018, 48, 1102-1110.	2.7	133
189	PsiconeuroinmunologÃa de los trastornos mentales. Revista De PsiquiatrÃa Y Salud Mental, 2018, 11, 115-124.	1.0	37
190	Altered neuro-inflammatory gene expression in hippocampus in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 82, 177-186.	2.5	108
191	Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. Acta Neuropsychiatrica, 2018, 30, 297-305.	1.0	10
192	Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort. Brain, Behavior, and Immunity, 2018, 69, 264-272.	2.0	86
193	Garcinia mangostana Linn displays antidepressant-like and pro-cognitive effects in a genetic animal model of depression: a bio-behavioral study in the Flinders Sensitive Line rat. Metabolic Brain Disease, 2018, 33, 467-480.	1.4	24
194	Aspirin and incident depressive symptoms: A longitudinal cohort study over 8Âyears. International Journal of Geriatric Psychiatry, 2018, 33, e193-e198.	1.3	8
195	A Case Series for Salmonella Carriers Who Presented with Psychosomatic Depressive Disorder and Showed Improvement after Ceftriaxone Treatment for 15 Days. Journal of Depression & Anxiety, 2018, 07, .	0.1	0
197	Inflammatory Signaling in Post-Stroke Fatigue and Depression. European Neurology, 2018, 80, 138-148.	0.6	54
198	Medications With Depression as an Adverse Effect. JAMA - Journal of the American Medical Association, 2018, 320, 1815.	3.8	3
199	Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression. Therapeutic Advances in Psychopharmacology, 2018, 8, 337-348.	1.2	50
200	Precision pharmacotherapy: psychiatry’s future direction in preventing, diagnosing, and treating mental disorders. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 211-222.	0.4	31

#	Article	IF	Citations
201	Neuroimmune and Inflammatory Signals in Complex Disorders of the Central Nervous System. NeuroImmunoModulation, 2018, 25, 246-270.	0.9	46
202	Inflamed depression. Lancet, The, 2018, 392, 1189-1190.	6.3	40
203	Inflammation and Depression: the Neuroimmune Connection. Current Treatment Options in Psychiatry, 2018, 5, 452-458.	0.7	9
204	The neuroscience of depressive disorders: A brief review of the past and some considerations about the future. Brain and Neuroscience Advances, 2018, 2, 239821281879926.	1.8	47
205	Role of Inflammation in Depression and Treatment Implications. Handbook of Experimental Pharmacology, 2018, 250, 255-286.	0.9	54
206	Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults. Expert Opinion on Pharmacotherapy, 2018, 19, 1541-1550.	0.9	23
207	Hashimotoâ€™s thyroiditis induces neuroinflammation and emotional alterations in euthyroid mice. Journal of Neuroinflammation, 2018, 15, 299.	3.1	27
208	Involvement of Innate and Adaptive Immune Systems Alterations in the Pathophysiology and Treatment of Depression. Frontiers in Neuroscience, 2018, 12, 547.	1.4	71
210	N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial. BMC Psychiatry, 2018, 18, 279.	1.1	22
211	The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. Neuroscience and Biobehavioral Reviews, 2018, 94, 219-237.	2.9	111
212	Immunization with Mycobacterium vaccae induces an anti-inflammatory milieu in the CNS: Attenuation of stress-induced microglial priming, alarmins and anxiety-like behavior. Brain, Behavior, and Immunity, 2018, 73, 352-363.	2.0	66
213	Effects of inflammation on social processes and implications for health. Annals of the New York Academy of Sciences, 2018, 1428, 5-13.	1.8	54
214	Neurogenesis, Inflammation, and Mental Health. , 2018, , 103-113.		1
215	Pathways Driving Neuroprogression in Depression: The Role of Immune Activation. , 2018, , 173-198.		1
216	Gene Expression of Inflammation Markers in Depression. , 2018, , 199-222.		1
217	Neuroimmunopharmacology at the Interface of Inflammation and Pharmacology Relevant to Depression. , 2018, , 223-240.		0
218	Stress, Maltreatment, Inflammation, and Functional Brain Changes in Depression. , 2018, , 267-285.		0
219	Inflammation and Depression in Patients With Autoimmune Disease, Diabetes, and Obesity. , 2018, , 377-392.		2

#	Article	IF	Citations
220	Does Inflammation Link Clinical Depression and Coronary Artery Disease?. , 2018, , 393-409.		0
221	Depression Subtypes and Inflammation: Atypical Rather Than Melancholic Depression Is Linked With Immunometabolic Dysregulations. , 2018, , 455-471.		3
222	Inflammation as a Marker of Clinical Response to Treatment: A Focus on Treatment-Resistant Depression. , 2018, , 473-487.		2
223	Clinical Trials of Anti-Inflammatory Treatments of Major Depression. , 2018, , 489-507.		2
224	Efficacy of Anti-Inflammatory Treatment in Depression. , 2018, , 525-538.		1
225	Is There Still Hope for Treating Depression With Antiinflammatories?. , 2018, , 569-580.		0
226	Future Perspectives on Immune-Related Treatments. , 2018, , 589-604.		0
227	SuHeXiang Essential Oil Inhalation Produces Antidepressant- and Anxiolytic-Like Effects in Adult Mice. Biological and Pharmaceutical Bulletin, 2018, 41, 1040-1048.	0.6	15
228	Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E. Nature Communications, 2018, 9, 2459.	5.8	65
229	Inflammation and fatigue in early, untreated Parkinson's Disease. Acta Neurologica Scandinavica, 2018, 138, 394-399.	1.0	23
230	TLR4-NF-Î²B Signal Involved in Depressive-Like Behaviors and Cytokine Expression of Frontal Cortex and Hippocampus in Stressed C57BL/6 and ob/ob Mice. Neural Plasticity, 2018, 2018, 1-12.	1.0	49
231	Inflammation: A Contributor to Depressive Comorbidity in Inflammatory Skin Disease. Skin Pharmacology and Physiology, 2018, 31, 246-251.	1.1	56
232	Replication and reproducibility issues in the relationship between C-reactive protein and depression: A systematic review and focused meta-analysis. Brain, Behavior, and Immunity, 2018, 73, 85-114.	2.0	99
234	Plasma disturbance of phospholipid metabolism in major depressive disorder by integration of proteomics and metabolomics. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1451-1461.	1.0	32
235	Depression severity is associated with increased inflammation in veterans with peripheral artery disease. Vascular Medicine, 2018, 23, 445-453.	0.8	14
236	The role of neuroinflammation and neurovascular dysfunction in major depressive disorder. Journal of Inflammation Research, 2018, Volume 11, 179-192.	1.6	83
237	The Food-Specific Serum IgG Reactivity in Major Depressive Disorder Patients, Irritable Bowel Syndrome Patients and Healthy Controls. Nutrients, 2018, 10, 548.	1.7	16
238	Insights into Macrophage Heterogeneity and Cytokine-Induced Neuroinflammation in Major Depressive Disorder. Pharmaceuticals, 2018, 11, 64.	1.7	46

#	Article	IF	Citations
239	Comparative effects of stressors on behavioral and neuroimmune responses of fawn-hooded (FH/Wjd) and Wistar rats: Implications for models of depression. Journal of Neuroimmunology, 2018, 322, 74-80.	1.1	4
240	Probiotics for the treatment of depressive symptoms: An anti-inflammatory mechanism?. Brain, Behavior, and Immunity, 2018, 73, 115-124.	2.0	90
241	Plasma IL-17A levels in patients with late-life depression. Revista Brasileira De Psiquiatria, 2018, 40, 212-215.	0.9	13
242	Immune and Neuroprotective Effects of Physical Activity on the Brain in Depression. Frontiers in Neuroscience, 2018, 12, 498.	1.4	44
243	Resolution of inflammation and mood disorders. Experimental and Molecular Pathology, 2018, 105, 190-201.	0.9	29
244	Abnormal hippocampal neurogenesis in Parkinsonâ€™s disease: relevance to a new therapeutic target for depression with Parkinsonâ€™s disease. Archives of Pharmacal Research, 2018, 41, 943-954.	2.7	59
245	Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response. Neuron, 2018, 99, 914-924.e3.	3.8	153
246	Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo. Trials, 2018, 19, 447.	0.7	47
247	Low on energy? An energy supply-demand perspective on stress and depression. Neuroscience and Biobehavioral Reviews, 2018, 94, 248-270.	2.9	33
248	Effects of Exercise Interventions on Depressive Symptoms Among Community-Dwelling Older Adults in the United States: A Systematic Review. Journal of Gerontological Nursing, 2018, 44, 31-38.	0.3	22
249	Sadness/Demoralisation and Apathy. , 2018, , 175-209.		0
250	Antenatal depression, psychotropic medication use, and inflammation among pregnant women. Archives of Women's Mental Health, 2018, 21, 785-790.	1.2	11
251	Plasma biomarkers in a placebo-controlled trial comparing tDCS and escitalopram efficacy in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 86, 211-217.	2.5	40
252	Biomarkers for Depression: Recent Insights, Current Challenges and Future Prospects. Focus (American Psychiatric Publishing), 2018, 16, 194-209.	0.4	19
253	Pathologic role of nitrergic neurotransmission in mood disorders. Progress in Neurobiology, 2019, 173, 54-87.	2.8	24
254	Effects of Psychosocial Stress on Subsequent Hemorrhagic Shock and Resuscitation in Male Mice. Shock, 2019, 51, 725-730.	1.0	10
255	A review on inflammatory cytokine-induced alterations of the brain as potential neural biomarkers in post-traumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 91, 103-112.	2.5	59
256	Beyond a neurotransmitter: The role of serotonin in inflammation and immunity. Pharmacological Research, 2019, 140, 100-114.	3.1	184

#	Article	IF	Citations
257	Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamineâ€™s Antidepressant Effect. Molecular Neurobiology, 2019, 56, 3484-3500.	1.9	59
258	Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. Molecular Psychiatry, 2019, 24, 869-887.	4.1	151
259	Inflammation in psychiatric disorders: what comes first?. Annals of the New York Academy of Sciences, 2019, 1437, 57-67.	1.8	292
260	The Role of Inflammation in Depression and Fatigue. Frontiers in Immunology, 2019, 10, 1696.	2.2	343
261	Invisible Designers: Brain Evolution Through the Lens of Parasite Manipulation. Quarterly Review of Biology, 2019, 94, 249-282.	0.0	10
262	Mechanisms and treatment of late-life depression. Translational Psychiatry, 2019, 9, 188.	2.4	285
263	Involvement of inflammatory gene expression pathways in depressed patients with hyperphagia. Translational Psychiatry, 2019, 9, 193.	2.4	15
264	Inflammation and remission in older patients with depression treated with electroconvulsive therapy; findings from the MODECT studyâœ°. Journal of Affective Disorders, 2019, 256, 509-516.	2.0	20
265	Total and ionized calcium and magnesium are significantly lowered in drug-naÃ¯ve depressed patients: effects of antidepressants and associations with immune activation. Metabolic Brain Disease, 2019, 34, 1493-1503.	1.4	18
267	Translational Medicine Strategies in Drug Development for Mood Disorders. Handbook of Behavioral Neuroscience, 2019, 29, 333-347.	0.7	0
268	Translational Medicine Strategies for Drug Development for Impulsive Aggression. Handbook of Behavioral Neuroscience, 2019, 29, 403-418.	0.7	0
269	Lifestyles and the risk of depression in the â€œSeguimiento Universidad de Navarraâ€•cohort. European Psychiatry, 2019, 61, 33-40.	0.1	28
270	Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychological Medicine, 2019, 49, 1958-1970.	2.7	385
271	Peripheral Biomarkers of Inflammation in Depression: Evidence from Animal Models and Clinical Studies. Methods in Molecular Biology, 2019, 2011, 467-492.	0.4	11
272	On-treatment improvement of an emerging psychosomatic depressive disorder among salmonella carriers: a multicenter experience from Egypt . Infection and Drug Resistance, 2019, Volume 12, 2573-2582.	1.1	3
273	The Gut Microbiota Links Dietary Polyphenols With Management of Psychiatric Mood Disorders. Frontiers in Neuroscience, 2019, 13, 1196.	1.4	61
274	Towards an Effective and Safe Treatment of Inflammatory Pain: A Delphi-Guided Expert Consensus. Advances in Therapy, 2019, 36, 2618-2637.	1.3	53
275	Leucineâ€“Histidine Dipeptide Attenuates Microglial Activation and Emotional Disturbances Induced by Brain Inflammation and Repeated Social Defeat Stress. Nutrients, 2019, 11, 2161.	1.7	19

#	Article	IF	Citations
276	Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders. Frontiers in Psychiatry, 2019, 10, 605.	1.3	43
277	The association between cortisol:C-reactive protein ratio and depressive fatigue is a function of CRP rather than cortisol . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2467-2475.	1.0	7
278	Physical activity and depression: Towards understanding the antidepressant mechanisms of physical activity. Neuroscience and Biobehavioral Reviews, 2019, 107, 525-539.	2.9	539
279	Use of non-steroidal anti-inflammatory drugs, aspirin and the risk of depression: The â€œSeguimiento Universidad de Navarra (SUN)â€•cohort. Journal of Affective Disorders, 2019, 247, 161-167.	2.0	8
280	Putative neuroprotective pharmacotherapies to target the staged progression of mental illness. Microbial Biotechnology, 2019, 13, 1032-1049.	0.9	34
281	The antidepressant impact of minocycline in rodents: A systematic review and meta-analysis. Scientific Reports, 2019, 9, 261.	1.6	23
282	Twelve Chinese herbal preparations for the treatment of depression or depressive symptoms in cancer patients: a systematic review and meta-analysis of randomized controlled trials. BMC Complementary and Alternative Medicine, 2019, 19, 28.	3.7	12
283	Neuroinflammation and cognition across psychiatric conditions. CNS Spectrums, 2019, 24, 4-15.	0.7	86
284	Neural mechanisms underlying adaptive and maladaptive consequences of stress: Roles of dopaminergic and inflammatory responses. Psychiatry and Clinical Neurosciences, 2019, 73, 669-675.	1.0	21
285	COX-2 Inhibitors, Aspirin, and Other Potential Anti-Inflammatory Treatments for Psychiatric Disorders. Frontiers in Psychiatry, 2019, 10, 375.	1.3	81
286	Sex differences in depressive-like behaviour may relate to imbalance of microglia activation in the hippocampus. Brain, Behavior, and Immunity, 2019, 81, 188-197.	2.0	87
287	Fast Green FCF Attenuates Lipopolysaccharide-Induced Depressive-Like Behavior and Downregulates TLR4/Myd88/NF-Îº B Signal Pathway in the Mouse Hippocampus. Frontiers in Pharmacology, 2019, 10, 501.	1.6	32
288	Nitric oxide: Antidepressant mechanisms and inflammation. Advances in Pharmacology, 2019, 86, 121-152.	1.2	29
289	Peripheral anti-inflammatory cytokine Interleukin-10 treatment mitigates interleukin-1Î² - induced anxiety and sickness behaviors in adult male rats. Behavioural Brain Research, 2019, 372, 112024.	1.2	31
290	Inflammation in Tic Disorders and Obsessive-Compulsive Disorder: Are PANS and PANDAS a Path Forward?. Journal of Child Neurology, 2019, 34, 598-611.	0.7	30
291	The efficacy of anti-inflammatory treatment interventions on depression in individuals with major depressive disorder and high levels of inflammation: A systematic review of randomized clinical trials. Physiology and Behavior, 2019, 207, 104-112.	1.0	13
292	Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study. CNS Drugs, 2019, 33, 685-694.	2.7	8
293	Inflammation and decreased functional connectivity in a widely-distributed network in depression: Centralized effects in the ventral medial prefrontal cortex. Brain, Behavior, and Immunity, 2019, 80, 657-666.	2.0	71

#	Article	IF	Citations
294	Supporting microglial niches for therapeutic benefit in psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 94, 109648.	2.5	5
295	The Interplay Between Stress, Inflammation, and Emotional Attention: Relevance for Depression. Frontiers in Neuroscience, 2019, 13, 384.	1.4	99
296	Neurobiology of Resilience: Interface Between Mind and Body. Biological Psychiatry, 2019, 86, 410-420.	0.7	175
297	The Influence of Antidepressants on the Immune System. Archivum Immunologiae Et Therapiae Experimentalis, 2019, 67, 143-151.	1.0	70
298	Curcumin in Depressive Disorders. , 2019, , 459-477.		0
299	Sericin alleviates restraint stress induced depressive- and anxiety-like behaviors via modulation of oxidative stress, neuroinflammation and apoptosis in the prefrontal cortex and hippocampus. Brain Research, 2019, 1715, 47-56.	1.1	61
300	Efficacy of antiâ€inflammatory treatment on major depressive disorder or depressive symptoms: metaâ€analysis of clinical trials. Acta Psychiatrica Scandinavica, 2019, 139, 404-419.	2.2	257
301	Matured Hop Bitter Acids in Beer Improve Lipopolysaccharide-Induced Depression-Like Behavior. Frontiers in Neuroscience, 2019, 13, 41.	1.4	15
302	Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients. Journal of Psychiatric Research, 2019, 113, 90-99.	1.5	111
303	The molecular and cellular mechanisms of depression: a focus on reward circuitry. Molecular Psychiatry, 2019, 24, 1798-1815.	4.1	125
304	Immunoneuropsychiatry â€" novel perspectives on brain disorders. Nature Reviews Neurology, 2019, 15, 317-328.	4.9	293
305	Canâ€™t or Wonâ€™t? Immunometabolic Constraints on Dopaminergic Drive. Trends in Cognitive Sciences, 2019, 23, 435-448.	4.0	88
306	Celecoxib augmentation of escitalopram in treatment-resistant bipolar depression and the effects on Quinolinic Acid. Neurology Psychiatry and Brain Research, 2019, 32, 22-29.	2.0	13
307	Animal models of major depressive disorder and the implications for drug discovery and development. Expert Opinion on Drug Discovery, 2019, 14, 365-378.	2.5	14
308	Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis. Brain, Behavior, and Immunity, 2019, 79, 24-38.	2.0	112
309	A clinical model for identifying an inflammatory phenotype in mood disorders. Journal of Psychiatric Research, 2019, 113, 148-158.	1.5	16
310	Roles of multiple lipid mediators in stress and depression. International Immunology, 2019, 31, 579-587.	1.8	41
311	The Hypothalamic-Pituitary-Adrenal Axis in Depression: Molecular Regulation, Pathophysiological Role, and Translational Implications. , 2019, , 89-96.		10

#	Article	IF	Citations
312	Depression and Cardiovascular Risk: Epidemiology, Mechanisms, and Implications. , 2019, , 185-196.		0
313	Targeting the immune system in the treatment of bipolar disorder. Psychopharmacology, 2019, 236, 2909-2921.	1.5	45
314	Depressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation?. Clinical and Experimental Immunology, 2019, 197, 308-318.	1.1	68
315	Inflammation, infection and depression: an evolutionary perspective. Evolutionary Human Sciences, 2019, 1, .	0.9	3
316	Depression. Current Opinion in Psychiatry, 2019, 32, 348-354.	3.1	57
317	Animal models of post-traumatic stress disorder and novel treatment targets. Behavioural Pharmacology, 2019, 30, 130-150.	0.8	45
318	New drug candidates for depression â€“ a nationwide populationâ€based study. Acta Psychiatrica Scandinavica, 2019, 139, 68-77.	2.2	58
319	TNF-Î± regulates microglial activation via the NF-ÎºB signaling pathway in systemic lupus erythematosus with depression. International Journal of Biological Macromolecules, 2019, 125, 892-900.	3.6	32
320	Depression and Neurocognitive Function in Chronic Kidney Disease. , 2019, , 237-249.e6.		1
321	Longitudinal association of inflammation with depressive symptoms: A 7-year cross-lagged twin difference study. Brain, Behavior, and Immunity, 2019, 75, 200-207.	2.0	51
322	FCPR16, a novel phosphodiesterase 4 inhibitor, produces an antidepressant-like effect in mice exposed to chronic unpredictable mild stress. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 90, 62-75.	2.5	22
323	Plasma and cerebrospinal fluid inflammatory cytokines in perinatal depression. American Journal of Obstetrics and Gynecology, 2019, 220, 271.e1-271.e10.	0.7	35
324	Inflammation and postâ€traumatic stress disorder. Psychiatry and Clinical Neurosciences, 2019, 73, 143-153.	1.0	206
325	Longitudinal Association Between Depression and Inflammatory Markers: Results From the Netherlands Study of Depression and Anxiety. Biological Psychiatry, 2019, 85, 829-837.	0.7	134
326	Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry,the, 2019, 6, 164-173.	3.7	238
327	Old Friends, immunoregulation, and stress resilience. Pflugers Archiv European Journal of Physiology, 2019, 471, 237-269.	1.3	45
328	Dietary inflammatory index and depression: a meta-analysis. Public Health Nutrition, 2019, 22, 654-660.	1.1	70
329	Psychological co-morbidities in COPD: Targeting systemic inflammation, a benefit for both?. European Journal of Pharmacology, 2019, 842, 99-110.	1.7	48

#	Article	IF	Citations
330	Fetal programming of neuropsychiatric disorders by maternal pregnancy depression: a systematic mini review. Pediatric Research, 2019, 85, 134-145.	1.1	30
331	The Role of Depressive Subtypes within the Neuroinflammation Hypothesis of Major Depressive Disorder. Neuroscience, 2019, 403, 93-110.	1.1	110
332	Depression and obesity: evidence of shared biological mechanisms. Molecular Psychiatry, 2019, 24, 18-33.	4.1	521
333	Blood-based biomarkers predicting response to antidepressants. Journal of Neural Transmission, 2019, 126, 47-63.	1.4	22
334	A joint study of whole exome sequencing and structural MRI analysis in major depressive disorder. Psychological Medicine, 2020, 50, 384-395.	2.7	19
335	Roadmap for Routine Pharmacogenetic Testing in a Psychiatric University Hospital. Pharmacopsychiatry, 2020, 53, 179-183.	1.7	4
336	The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder. World Journal of Biological Psychiatry, 2020, 21, 775-783.	1.3	27
337	Cytokine concentrations are related to level of mental distress in inpatients not using anti-inflammatory drugs. Acta Neuropsychiatrica, 2020, 32, 23-31.	1.0	5
338	The depressogenic potential of added dietary sugars. Medical Hypotheses, 2020, 134, 109421.	0.8	21
339	Persistent depressive symptoms, HPA-axis hyperactivity, and inflammation: the role of cognitive-affective and somatic symptoms. Molecular Psychiatry, 2020, 25, 1130-1140.	4.1	138
340	Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. Molecular Psychiatry, 2020, 25, 1275-1285.	4.1	106
341	Potential application of helminth therapy for resolution of neuroinflammation in neuropsychiatric disorders. Metabolic Brain Disease, 2020, 35, 95-110.	1.4	6
342	Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience. Neurobiology of Disease, 2020, 135, 104578.	2.1	38
343	Valeriana fauriei Exerts Antidepressant-Like Effects Through Anti-inflammatory and Antioxidant Activities by Inhibiting Brain-Derived Neurotrophic Factor Associated with Chronic Restraint Stress. Rejuvenation Research, 2020, 23, 245-255.	0.9	9
344	Treatment of Psychiatric Disorders in Chronic Kidney Disease Patients. , 2020, , 1123-1140.		2
345	Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 21-32.	0.9	129
346	Posttraumatic Stress Disorder and Inflammation: Untangling Issues of Bidirectionality. Biological Psychiatry, 2020, 87, 885-897.	0.7	70
347	Prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Depression among Adults with Inflammatory Chronic Conditions in the United States. Psychiatric Quarterly, 2020, 91, 209-221.	1.1	3

#	Article	IF	Citations
348	Microglial regional heterogeneity and its role in the brain. Molecular Psychiatry, 2020, 25, 351-367.	4.1	292
349	Depression in the medically ill. Australian and New Zealand Journal of Psychiatry, 2020, 54, 346-366.	1.3	24
350	Peripheral Blood Cellâ€“Stratified Subgroups of Inflamed Depression. Biological Psychiatry, 2020, 88, 185-196.	0.7	89
352	Systemic neuro-dysregulation in depression: Evidence from genome-wide association. European Neuropsychopharmacology, 2020, 39, 1-18.	0.3	9
353	The complex interplay between depression and multimorbidity in late life: risks and pathways. Mechanisms of Ageing and Development, 2020, 192, 111383.	2.2	60
354	Design, synthesis and biological evaluation of vortioxetine derivatives as new COX-1/2 inhibitors in human monocytes. Bioorganic and Medicinal Chemistry, 2020, 28, 115760.	1.4	10
355	Major Depressive Disorder Is Associated With Differential Expression of Innate Immune and Neutrophil-Related Gene Networks in Peripheral Blood: A Quantitative Review of Whole-Genome Transcriptional Data From Case-Control Studies. Biological Psychiatry, 2020, 88, 625-637.	0.7	43
356	Basal and LPS-stimulated inflammatory markers and the course of individual symptoms of depression. Translational Psychiatry, 2020, 10, 235.	2.4	48
357	Immune dysregulation in depression: Evidence from genome-wide association. Brain, Behavior, & Immunity - Health, 2020, 7, 100108.	1.3	10
358	hUC-MSCs ameliorated CUMS-induced depression by modulating complement C3 signaling-mediated microglial polarization during astrocyte-microglia crosstalk. Brain Research Bulletin, 2020, 163, 109-119.	1.4	23
359	Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders. Molecules, 2020, 25, 5388.	1.7	15
360	Depressive-like behaviors in mice with Imiquimod-induced psoriasis. International Immunopharmacology, 2020, 89, 107057.	1.7	10
361	Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2097002.	1.2	25
362	Peripheral Markers of Depression. Journal of Clinical Medicine, 2020, 9, 3793.	1.0	99
363	Infections, inflammation, and risk of neuropsychiatric disorders: the neglected role of â€œco-infectionâ€• Heliyon, 2020, 6, e05645.	1.4	17
364	Soothing liver-qi stagnation method for cancer-related depression. Medicine (United States), 2020, 99, e22797.	0.4	3
365	The genetic double whammy â€“ Autoimmune and mental health disorders. Brain, Behavior, and Immunity, 2020, 89, 7-8.	2.0	1
367	In Vivo TSPO Signal and Neuroinflammation in Alzheimerâ€™s Disease. Cells, 2020, 9, 1941.	1.8	51

#	Article	IF	Citations
368	Sick for science: experimental endotoxemia as a translational tool to develop and test new therapies for inflammation-associated depression. Molecular Psychiatry, 2021, 26, 3672-3683.	4.1	54
369	Telomere attrition and inflammatory load in severe psychiatric disorders and in response to psychotropic medications. Neuropsychopharmacology, 2020, 45, 2229-2238.	2.8	21
370	Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments. Genes, 2020, 11, 1089.	1.0	17
371	The Emerging Role of SGK1 (Serum- and Glucocorticoid-Regulated Kinase 1) in Major Depressive Disorder: Hypothesis and Mechanisms. Frontiers in Genetics, 2020, 11, 826.	1.1	28
372	The Innate Immune System and Inflammatory Priming: Potential Mechanistic Factors in Mood Disorders and Gulf War Illness. Frontiers in Psychiatry, 2020, 11, 704.	1.3	15
373	Study on the Role of Inflammatory Markers and Type D Personality on Symptom Profiles and Severity in Patients with Major Depressive Disorder. Applied Sciences (Switzerland), 2020, 10, 5615.	1.3	0
374	Rheumatoid Arthritis, Depression, and the Role of Celecoxib. SN Comprehensive Clinical Medicine, 2020, 2, 1848-1852.	0.3	1
375	Can precision medicine advance psychiatry?. Irish Journal of Psychological Medicine, 2020, 38, 1-6.	0.7	6
376	Investigating the Convergent Mechanisms between Major Depressive Disorder and Parkinsonâ€™s Disease. Complex Psychiatry, 2020, 6, 47-61.	1.3	13
377	DepresiÃ³n e inflamaciÃ³n: Â¿Una relaciÃ³n mÃ¡s allÃ¡ del azar?. Revista MÃ©dica ClÃ¬nica Las Condes, 2020, 31, 188-196.	0.2	0
378	The Pelvic Girdle Pain deadlock: 2. Topics that, so far, have remained out of focus. Musculoskeletal Science and Practice, 2020, 48, 102166.	0.6	8
379	The effects of ginger supplementation on biomarkers of inflammation and oxidative stress in adults: A systematic review and meta-analysis of randomized controlled trials. Journal of Herbal Medicine, 2020, 22, 100364.	1.0	8
380	Changes in interleukin-1 beta induced by rTMS are significantly correlated with partial improvement of cognitive dysfunction in treatment-resistant depression: a pilot study. Psychiatry Research, 2020, 289, 112995.	1.7	14
381	The impact of Dl-3-n-butylphthalide on the lipidomics of the hippocampus in a rat model of lipopolysaccharide-induced depression. Prostaglandins and Other Lipid Mediators, 2020, 150, 106464.	1.0	3
382	Getting under the skin: Does biology help predict chronicity of depression?. Journal of Affective Disorders, 2020, 274, 1013-1021.	2.0	3
383	Inflammation as a treatment target in mood disorders: review. BJPsych Open, 2020, 6, e60.	0.3	54
384	Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOrT) metric for a personalised psychiatry. BMC Medicine, 2020, 18, 170.	2.3	21
385	NLRP1 inflammasome contributes to chronic stress-induced depressive-like behaviors in mice. Journal of Neuroinflammation, 2020, 17, 178.	3.1	109

#	Article	IF	Citations
386	What is the potential of statins in the treatment of depression?. Expert Review of Neurotherapeutics, 2020, 20, 307-309.	1.4	0
387	GSK3Î²: A Master Player in Depressive Disorder Pathogenesis and Treatment Responsiveness. Cells, 2020, 9, 727.	1.8	42
388	Association between C-reactive protein and mood disorder in a representative sample of the Canadian population: analysis of CHMS data 2013â€“2014. Canadian Journal of Public Health, 2020, 111, 743-751.	1.1	2
389	Immune processes and risk of psychosis. , 2020, , 211-227.		0
390	Immune biomarkers alterations in post-traumatic stress disorder: A systematic review and meta-analysis. Journal of Affective Disorders, 2020, 268, 39-46.	2.0	72
391	Effects of vitamin D and/or magnesium supplementation on mood, serum levels of BDNF, inflammatory biomarkers, and SIRT1 in obese women: a study protocol for a double-blind, randomized, placebo-controlled trial. Trials, 2020, 21, 225.	0.7	18
392	Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology, 2020, 45, 990-997.	2.8	127
393	Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-Î± inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. BMC Rheumatology, 2020, 4, 9.	0.6	9
394	Antidepressants in inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 184-192.	8.2	47
395	Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain, Behavior, and Immunity, 2020, 87, 901-909.	2.0	381
396	Increased brain vitamin D receptor expression and decreased expression of cathelicidin antimicrobial peptide in individuals who died by suicide. Journal of Psychiatric Research, 2020, 125, 75-84.	1.5	7
397	Fecal transplant prevents gut dysbiosis and anxiety-like behaviour after spinal cord injury in rats. PLoS ONE, 2020, 15, e0226128.	1.1	77
398	Inflammation, depression, and anxiety disorder: A population-based study examining the association between Interleukin-6 and the experiencing of depressive and anxiety symptoms. Psychiatry Research, 2020, 285, 112809.	1.7	15
399	Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression. Biological Psychiatry, 2020, 88, 369-380.	0.7	209
400	Psychological outcomes following surgical and endoscopic bariatric procedures: A systematic review. Obesity Reviews, 2020, 21, e12998.	3.1	54
401	An integrated meta-analysis of peripheral blood metabolites and biological functions in major depressive disorder. Molecular Psychiatry, 2021, 26, 4265-4276.	4.1	119
402	Role of Somatostatin in the Regulation of Central and Peripheral Factors of Satiety and Obesity. International Journal of Molecular Sciences, 2020, 21, 2568.	1.8	30
403	CD4+CD25+ T Cells are Essential for Behavioral Effects of Lactobacillus rhamnosus JB-1 in Male BALB/c mice. Brain, Behavior, and Immunity, 2020, 88, 451-460.	2.0	30

#	Article	IF	Citations
404	Altered peripheral blood compounds in drug-naÃ¯ve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis. Brain, Behavior, and Immunity, 2020, 88, 547-558.	2.0	96
405	The association between aspirin use and depression: a systematic review and metaâ€analysis of observational studies. Pharmacoepidemiology and Drug Safety, 2020, 29, 613-622.	0.9	12
406	Enhanced conditioning of adverse memories in the mouse modified swim test is associated with neuroinflammatory changes â€“ Effects that are susceptible to antidepressants. Neurobiology of Learning and Memory, 2020, 172, 107227.	1.0	11
407	Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms. JAMA Psychiatry, 2021, 78, 161.	6.0	150
408	Evaluation of various estimators for standardized mean difference in metaâ€analysis. Statistics in Medicine, 2021, 40, 403-426.	0.8	76
409	Depression, Anxiety, and Self-Directed Violence in Women With Endometriosis: A Retrospective Matched-Cohort Study. American Journal of Epidemiology, 2021, 190, 843-852.	1.6	27
410	Treatment for comorbid depressive disorder or subthreshold depression in diabetes mellitus: Systematic review and metaâ€analysis. Brain and Behavior, 2021, 11, e01981.	1.0	57
411	Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. Pharmacological Reviews, 2021, 73, 202-277.	7.1	110
412	Neuroimmunology of depression. Advances in Pharmacology, 2021, 91, 259-292.	1.2	13
413	Novel therapeutic drug targets for bipolar disorder. , 2021, , 393-404.		0
414	Blood-brain barrierâ€™s interplay with peripheral and central inflammation as a pathophysiological mechanism of bipolar disorders. , 2021, , 143-153.		1
415	Anxiety and depression predispose individuals to an autoimmune bullous diseases- bullous pemphigoid: A large-scale population-based cohort study. Current Psychology, 2022, 41, 8945-8955.	1.7	6
416	Risky emotional family environment in childhood and depressionâ€related cytokines in adulthood: The protective role of compassion. Developmental Psychobiology, 2021, 63, 1190-1201.	0.9	7
417	Treatment resistant depression. , 2021, , 33-84.		0
418	Immunomodulation of Resistant Depression. , 2021, , 389-400.		0
419	Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. Neuropsychopharmacology, 2021, 46, 939-948.	2.8	125
420	Neurotoxicity in Depression. , 2021, , 1-30.		0
421	Pharmacological or non-pharmacological interventions for treatment of common mental disorders associated with Tuberculosis: A systematic review. Chronic Respiratory Disease, 2021, 18, 147997312110039.	1.0	9

#	Article	IF	Citations
422	Biological Evaluation of Aegle marmelos Fruit Extract and Isolated Aegeline in Alleviating Painâ€“Depression Dyad: In Silico Analysis of Aegeline on MAO-A and iNOS. ACS Omega, 2021, 6, 2034-2044.	1.6	5
423	Immunity as a Common Risk Pathway for Psychiatric and Medical Comorbidity. , 2021, , 41-50.		0
424	Molecular mechanisms of neurodegeneration in neuropsychiatric diseases. , 2021, , 149-180.		0
425	Alterations observed in the interferon Î± and Î² signaling pathway in MDD patients are marginally influenced by cis-acting alleles. Scientific Reports, 2021, 11, 727.	1.6	1
426	Synaptic Microenvironment in Depressive Disorder: Insights from Synaptic Plasticity. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 157-165.	1.0	5
427	Autoimmune Diseases and Infections as Risk Factors for Mental Disorders. , 2021, , 3-16.		0
428	Inflammatory Depressionâ€"Mechanisms and Non-Pharmacological Interventions. International Journal of Molecular Sciences, 2021, 22, 1640.	1.8	43
429	PTPN22 gene functional polymorphism (rs2476601) in older adults with frailty syndrome. Molecular Biology Reports, 2021, 48, 1193-1204.	1.0	1
430	Oxolipidomics profile in major depressive disorder: Comparing remitters and non-remitters to repetitive transcranial magnetic stimulation treatment. PLoS ONE, 2021, 16, e0246592.	1.1	10
431	Microglial activation elicits a negative affective state through prostaglandin-mediated modulation of striatal neurons. Immunity, 2021, 54, 225-234.e6.	6.6	91
432	Treatment-Resistant Depression Revisited: A Glimmer of Hope. Journal of Personalized Medicine, 2021, 11, 155.	1.1	44
433	Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment. Frontiers in Medicine, 2021, 8, 608083.	1.2	5
434	Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression. Journal of Neuroinflammation, 2021, 18, 38.	3.1	46
435	Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder. Journal of Experimental Pharmacology, 2021, Volume 13, 181-196.	1.5	5
436	Bipolar disorder: An evolutionary psychoneuroimmunological approach. Neuroscience and Biobehavioral Reviews, 2021, 122, 28-37.	2.9	38
437	Physical activity and depression in older adults: the knowns and unknowns. Psychiatry Research, 2021, 297, 113738.	1.7	39
438	The Potential of Hydrogen for Improving Mental Disorders. Current Pharmaceutical Design, 2021, 27, 695-702.	0.9	2
439	Prefrontal dopamine D1 receptor manipulation influences anxiety behavior and induces neuroinflammation within the hippocampus. International Journal of Bipolar Disorders, 2021, 9, 9.	0.8	7

#	Article	IF	Citations
440	Inhibition of acid sphingomyelinase increases regulatory T cells in humans. Brain Communications, 2021, 3, fcab020.	1.5	11
441	Assessing the links between childhood trauma, C-reactive protein and response to antidepressant treatment in patients with affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1331-1341.	1.8	4
442	Expansion of CD4 T Lymphocytes Expressing Interleukin 17 and Tumor Necrosis Factor in Patients with Major Depressive Disorder. Journal of Personalized Medicine, 2021, 11, 220.	1.1	32
443	Highlighting the Role of Universally Available and Innate Immune Cell Counts in Acute Ischemic Stroke: A Scoping Review. Sustainability, 2021, 13, 4069.	1.6	1
444	Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities. Frontiers in Neuroscience, 2021, 15, 650785.	1.4	31
446	Major Depressive Disorder in Older Patients as an Inflammatory Disorder: Implications for the Pharmacological Management of Geriatric Depression. Drugs and Aging, 2021, 38, 451-467.	1.3	9
447	Depressive symptoms, childhood maltreatment, and allostatic load: The importance of sex differences. Psychoneuroendocrinology, 2021, 126, 105130.	1.3	10
448	SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders. Cytokine and Growth Factor Reviews, 2021, 58, 1-15.	3.2	84
449	Brain-immune crosstalk in the treatment of major depressive disorder. European Neuropsychopharmacology, 2021, 45, 89-107.	0.3	41
450	Hippocampal Glycerol-3-Phosphate Acyltransferases 4 and BDNF in the Progress of Obesity-Induced Depression. Frontiers in Endocrinology, 2021, 12, 667773.	1.5	8
451	Interleukin-6 secretion upon acute psychosocial stress as a potential predictor of psychotherapy outcome in posttraumatic stress disorder. Journal of Neural Transmission, 2021, 128, 1301-1310.	1.4	10
452	Results of the Optimune trial: A randomized controlled trial evaluating a novel Internet intervention for breast cancer survivors. PLoS ONE, 2021, 16, e0251276.	1.1	25
453	Gene expression signatures differentiating major depressive disorder from subsyndromal symptomatic depression. Aging, 2021, 13, 13124-13137.	1.4	2
454	Inflammation is associated with future depressive symptoms among older adults. Brain, Behavior, & Immunity - Health, 2021, 13, 100226.	1.3	13
455	Post-traumatic stress disorder and its association with stroke and stroke risk factors: A literature review. Neurobiology of Stress, 2021, 14, 100332.	1.9	20
456	Inflammationâ€driven brain and gut barrier dysfunction in stress and mood disorders. European Journal of Neuroscience, 2022, 55, 2851-2894.	1.2	54
457	The Impact of Obesity on Microglial Function: Immune, Metabolic and Endocrine Perspectives. Cells, 2021, 10, 1584.	1.8	31
458	How environmental enrichment balances out neuroinflammation in chronic pain and comorbid depression and anxiety disorders. British Journal of Pharmacology, 2022, 179, 1640-1660.	2.7	25

#	Article	IF	Citations
459	Searching for host immune-microbiome mechanisms in obsessive-compulsive disorder: A narrative literature review and future directions. Neuroscience and Biobehavioral Reviews, 2021, 125, 517-534.	2.9	5
460	Neuroinflammation as a Common Denominator of Complex Diseases (Cancer, Diabetes Type 2, and) Tj ETQq1 1 0.784314 rgBT /Over	1.8	16
461	Catalpol ameliorates depressive-like behaviors in CUMS mice via oxidative stress-mediated NLRP3 inflammasome and neuroinflammation. Translational Psychiatry, 2021, 11, 353.	2.4	58
462	Toxoplasma gondii, Suicidal Behavior, and Intermediate Phenotypes for Suicidal Behavior. Frontiers in Psychiatry, 2021, 12, 665682.	1.3	19
463	C-Reactive Protein as a Potential Biomarker in Psychiatric Practice: Are We There Yet?. World Journal of Biological Psychiatry, 2021, , 1-37.	1.3	4
464	Mechanisms and Treatment of Late-Life Depression. Focus (American Psychiatric Publishing), 2021, 19, 340-354.	0.4	2
465	Inflammation and Depression: A Public Health Perspective. Brain, Behavior, and Immunity, 2021, 95, 1-3.	2.0	25
466	Depression in late life: Linking the immunometabolic dysregulation with clinical features. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 181-185.	1.0	0
467	Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications. Pharmacological Reviews, 2021, 73, 1084-1117.	7.1	36
468	Randomized study of the effects of vitamin D and/or magnesium supplementation on mood, serum levels of BDNF, inflammation, and SIRT1 in obese women with mild to moderate depressive symptoms. Nutritional Neuroscience, 2022, 25, 2123-2135.	1.5	16
469	Does the Interaction between Local and Systemic Inflammation Provide a Link from Psychology and Lifestyle to Tissue Health in Musculoskeletal Conditions?. International Journal of Molecular Sciences, 2021, 22, 7299.	1.8	16
470	Inflamed brain: Targeting immune changes and inflammation for treatment of depression. Psychiatry and Clinical Neurosciences, 2021, 75, 304-311.	1.0	23
471	Circadian depression: A mood disorder phenotype. Neuroscience and Biobehavioral Reviews, 2021, 126, 79-101.	2.9	50
472	Mood disorder and cancer onset: evidence from a population-based sample of Australian women. Revista Brasileira De Psiquiatria, 2021, 43, 355-361.	0.9	1
473	Integrating the monoamine and cytokine hypotheses of depression: Is histamine the missing link?. European Journal of Neuroscience, 2022, 55, 2895-2911.	1.2	11
474	Highlighting Immune System and Stress in Major Depressive Disorder, Parkinsonâ€™s, and Alzheimerâ€™s Diseases, with a Connection with Serotonin. International Journal of Molecular Sciences, 2021, 22, 8525.	1.8	18
475	Targeting NLRP3 Inflammasome in Translational Treatment of Nervous System Diseases: An Update. Frontiers in Pharmacology, 2021, 12, 707696.	1.6	25
476	Research Progress on Natural Compounds Exerting an Antidepressant Effect through Anti-inflammatory. Current Medicinal Chemistry, 2022, 29, 934-956.	1.2	4

#	Article	IF	Citations
477	The anti-inflammatory drugs ibuprofen, celecoxib, and etanercept prevented cyclosporine A form initiating depression-like behavior in mice. Hacettepe University Journal of the Faculty of Pharmacy, 0, , .	0.0	0
478	Tumor necrosis factorâ€Î± expression aberration of <scp>M1</scp>/<scp>M2</scp> macrophages in adult h<scp>ighâ€functioning</scp> autism spectrum disorder. Autism Research, 2021, 14, 2330-2341.	2.1	11
479	Clinical predictors of incident somatic morbidity in a sample of depressed patients: A 16â€“30 years follow-up study. European Journal of Psychiatry, 2021, , .	0.7	0
480	Immunotherapies for Depression. , 2021, , 139-163.		0
481	Inflammation, Sickness Behaviour and Depression. , 2021, , 109-138.		1
482	Different Sides of Depression in the Elderly: An In-depth View on the Role of AÎ² Peptides. Current Medicinal Chemistry, 2022, 29, 5731-5757.	1.2	7
483	A Potential Interface between the Kynurenine Pathway and Autonomic Imbalance in Schizophrenia. International Journal of Molecular Sciences, 2021, 22, 10016.	1.8	5
484	Potential use of albumin and neutrophilâ€toâ€lymphocyte ratio to guide the evaluation and treatment of cancerâ€related depression and anxiety. Psycho-Oncology, 2021, , .	1.0	1
485	Biobehavioral Research and Hematopoietic Stem Cell Transplantation: Expert Review from the Biobehavioral Research Special Interest Group of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 747-757.	0.6	10
486	Prolonged saturated, but not monounsaturated, high-fat feeding provokes anxiodepressive-like behaviors in female mice despite similar metabolic consequences. Brain, Behavior, & Immunity - Health, 2021, 16, 100324.	1.3	4
487	Elevated inflammatory markers in women with remitted major depressive disorder and the role of early life maltreatment. Brain, Behavior, and Immunity, 2021, 97, 219-225.	2.0	8
488	Polymorphisms in the IL1-b gene are associated with increased Glu and Glx levels in treatment-resistant depression. Psychiatry Research - Neuroimaging, 2021, 316, 111348.	0.9	0
489	Basal and LPS-stimulated inflammatory markers and the course of anxiety symptoms. Brain, Behavior, and Immunity, 2021, 98, 378-387.	2.0	13
490	Cerebrospinal fluid test results and associations with subsequent mental disorders, neurological diseases, and CNS infections: A population-based cohort study. Brain, Behavior, and Immunity, 2021, 98, 210-218.	2.0	4
491	Targeting hippocampal phospholipid and tryptophan metabolism for antidepressant-like effects of albiflorin. Phytomedicine, 2021, 92, 153735.	2.3	20
492	No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. European Neuropsychopharmacology, 2021, 53, 34-46.	0.3	22
493	Nutritional therapy can reduce the burden of depression management in low income countries: A review. IBRO Neuroscience Reports, 2021, 11, 15-28.	0.7	6
494	A chicken and egg scenario in psychoneuroimmunology: Bidirectional mechanisms linking cytokines and depression. Journal of Affective Disorders Reports, 2021, 6, 100177.	0.9	9

#	Article	IF	Citations
495	The emerging tale of microglia in psychiatric disorders. Neuroscience and Biobehavioral Reviews, 2021, 131, 1-29.	2.9	53
496	Translational evidence for the Inflammatory Response System (IRS)/Compensatory Immune Response System (CIRS) and neuroprogression theory of major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110343.	2.5	37
497	Licofelone, a potent COX/5-LOX inhibitor and a novel option for treatment of neurological disorders. Prostaglandins and Other Lipid Mediators, 2021, 157, 106587.	1.0	17
498	Cytokine Effects on Neuronal Processes and on Behavior. , 2022, , 728-731.		0
499	The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. Translational Psychiatry, 2021, 11, 58.	2.4	36
500	Antidepressiva. , 2017, , 1-200.		1
501	Introduction. Advances in Experimental Medicine and Biology, 2019, 1180, 1-17.	0.8	3
502	Salvianolic acid B promotes microglial M2-polarization and rescues neurogenesis in stress-exposed mice. Brain, Behavior, and Immunity, 2017, 66, 111-124.	2.0	93
503	PPARÎ³-mediated microglial activation phenotype is involved in depressive-like behaviors and neuroinflammation in stressed C57BL/6J and ob/ob mice. Psychoneuroendocrinology, 2020, 117, 104674.	1.3	25
504	Challenges in researching the immune pathways between early life adversity and psychopathology. Development and Psychopathology, 2020, 32, 1597-1624.	1.4	20
505	Depression in Poststroke Aphasia. American Journal of Speech-Language Pathology, 2020, 29, 1798-1810.	0.9	21
508	Protocol for the Optimune trial: a randomized controlled trial evaluating a novel Internet intervention for breast cancer survivors. Trials, 2020, 21, 117.	0.7	8
509	C-reactive protein and clinical subtypes of major depressive disorder at Zagazig University Hospitals. Middle East Current Psychiatry, 2020, 27, .	0.5	6
510	Large-scale evidence for an association between low-grade peripheral inflammation and brain structural alterations in major depression in the BiDirect study. Journal of Psychiatry and Neuroscience, 2019, 44, 423-431.	1.4	29
512	Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment. Current Neuropharmacology, 2016, 14, 674-687.	1.4	55
513	Therapeutic Strategies for Treatment of Inflammation-related Depression. Current Neuropharmacology, 2018, 16, 176-209.	1.4	107
514	Imaging the Role of Inflammation in Mood and Anxiety-related Disorders. Current Neuropharmacology, 2018, 16, 533-558.	1.4	270
515	The Emerging Role of the Double-Edged Impact of Arachidonic Acid- Derived Eicosanoids in the Neuroinflammatory Background of Depression.. Current Neuropharmacology, 2020, 19, 278-293.	1.4	14

#	Article	IF	Citations
516	Plasma Indoleamine-2,3-Dioxygenase (IDO) is Increased in Drug-NaÃ¯ ve Major Depressed Patients and Treatment with Sertraline and Ketoprofen Normalizes IDO in Association with Pro-Inflammatory and Immune- Regulatory Cytokines. CNS and Neurological Disorders - Drug Targets, 2020, 19, 44-54.	0.8	19
517	Effects of troxerutin on anxiety- and depressive-like behaviors induced by chronic mild stress in adult male rats. Iranian Journal of Basic Medical Sciences, 2018, 21, 781-786.	1.0	9
518	Immunological aspects of the treatment of depression and schizophrenia. Dialogues in Clinical Neuroscience, 2017, 19, 55-63.	1.8	63
519	Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders. Dialogues in Clinical Neuroscience, 2017, 19, 27-36.	1.8	12
520	A multispecies approach for understanding neuroimmune mechanisms of stress. Dialogues in Clinical Neuroscience, 2017, 19, 37-53.	1.8	29
521	Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues in Clinical Neuroscience, 2018, 20, 63-73.	1.8	288
522	Anti-Inflammatory Agents as Antidepressants: Truth or Dare. Psychiatric Annals, 2015, 45, 255-261.	0.1	3
523	Immunoinflammatory Therapies in Psychiatry: Current Evidence Base. Indian Journal of Psychological Medicine, 2017, 39, 721-726.	0.6	3
524	Depression and Inflammation: Disentangling a Clear Yet Complex and Multifaceted Link. Neuropsychiatry, 2018, 07, .	0.4	25
525	Hepatic encephalopathy and depression in chronic liver disease: is the common link systemic inflammation?. Analytical Biochemistry, 2022, 636, 114437.	1.1	7
526	Rethinking stress resilience. Trends in Neurosciences, 2021, 44, 936-945.	4.2	21
527	Î´_{EPCD}: the electrophysiologic coefficient of depressiveness. Biomarkers, 2021, 26, 752-759.	0.9	0
528	Association Between Systemic Inflammation and Individual Symptoms of Depression: A Pooled Analysis of 15 Population-Based Cohort Studies. American Journal of Psychiatry, 2021, 178, 1107-1118.	4.0	72
529	Anti-Inflammatory and Immune-Modulatory Therapeutic Approaches in Major Depression. , 2016, , 115-141.		0
530	Effect of Interacting Nonsteroidal Anti-Inflammatory Agents (NSAIDs) and Opioids on Mood. , 2016, , 111-119.		0
531	Psychoneuroimmunologische Grundlagen psychischer Erkrankungen. , 2016, , 1-21.		0
532	Complementation of Pharmacogenetics with Biomarkers and Neuroimaging in Major Depression. , 2016, , 67-92.		0
533	Pharmacoresistant depression - what is the next step?. Psychiatrie Pro Praxi, 2016, 17, 92-95.	0.0	0

#	Article	IF	Citations
534	Psychoneuroimmunologische Grundlagen psychischer Erkrankungen. , 2017, , 291-310.		0
535	Analgetika. , 2018, , 447-696.		0
536	Lâ€™immunopsychiatrie existe-t-elle ?. Phytotherapie, 2018, 16, 347-352.	0.1	0
537	Immunological Aspects of Depressive Disorder â€“ The Review. Serbian Journal of Experimental and Clinical Research, 2019, .	0.2	0
538	Treating psychiatric symptoms and disorders with non-psychotropic medications. Dialogues in Clinical Neuroscience, 2019, 21, 193-201.	1.8	0
541	Anti-Inflammatory Effects of Curcumin in the Inflammatory Diseases: Status, Limitations and Countermeasures. Drug Design, Development and Therapy, 2021, Volume 15, 4503-4525.	2.0	186
542	Neurobiological Principles: Psycho-Neuro-Immuno-Endocrinology. , 2020, , 1-40.		1
543	Depression as an Immunometabolic Disorder: Exploring Shared Pharmacotherapeutics with Cardiovascular Disease. Current Neuropharmacology, 2020, 18, 1138-1153.	1.4	10
544	A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa. European Psychiatry, 2021, 64, e71.	0.1	20
545	Depression in late life: Linking the immunometabolic dysregulation with clinical features. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 181-185.	0.2	0
546	A case of treatment-resistant depression in an older adult and a discussion of treatment options. BJPsych Bulletin, 2021, , 1-6.	0.7	1
547	Cerebral Structural Abnormalities and Their Associations With Peripheral Cytokine Levels in a Group of Untreated Patients With Nasopharyngeal Carcinoma. Frontiers in Oncology, 2021, 11, 740033.	1.3	2
548	Neuropsychiatric disorders: An immunological perspective. Advances in Immunology, 2021, 152, 83-155.	1.1	10
549	Inflammatory cytokines and callosal white matter microstructure in adolescents. Brain, Behavior, and Immunity, 2022, 100, 321-331.	2.0	10
550	Perinatal mental illness and maternal autoimmune disease: A review of current evidence and avenues for future research. Frontiers in Neuroendocrinology, 2022, 65, 100975.	2.5	3
551	Distinct Proteomic Profiles in Prefrontal Subareas of Major Depressive Disorder and Bipolar Disorder Patients. SSRN Electronic Journal, 0, , .	0.4	0
552	C-Reactive Protein as a Biomarker for Major Depressive Disorder?. International Journal of Molecular Sciences, 2022, 23, 1616.	1.8	39
553	Immune targets for therapeutic development in depression: towards precision medicine. Nature Reviews Drug Discovery, 2022, 21, 224-244.	21.5	88

#	Article	IF	Citations
554	Precision medicine to manage chronic immune-related conditions. , 2022, , 295-318.		1
555	Oridonin Alleviates LPS-Induced Depression by Inhibiting NLRP3 Inflammasome via Activation of Autophagy. Frontiers in Medicine, 2021, 8, 813047.	1.2	13
556	NSAID use and unnatural deaths after cancer diagnosis: a nationwide cohort study in Sweden. BMC Cancer, 2022, 22, 75.	1.1	0
557	Food supplements to complement brain functioning: the benefits of a combination of magnesium, folic acid, omega-3 fatty acids and vitamin E. F1000Research, 0, 11, 140.	0.8	1
558	Analgetika. , 2022, , 511-774.		0
559	Hippocampal Over-Expression of Cyclooxygenase-2 (COX-2) Is Associated with Susceptibility to Stress-Induced Anhedonia in Mice. International Journal of Molecular Sciences, 2022, 23, 2061.	1.8	14
560	Antidepressant Prescription for Major Depressive Disorder: Results from a Population-Based Study in Italy. Current Neuropharmacology, 2022, 20, 2381-2392.	1.4	1
561	Is the Therapeutic Mechanism of Repetitive Transcranial Magnetic Stimulation in Cognitive Dysfunctions of Depression Related to the Neuroinflammatory Processes in Depression?. Frontiers in Psychiatry, 2022, 13, 834425.	1.3	7
562	Exploring the Potential Antidepressant Mechanisms of Pinellia by Using the Network Pharmacology and Molecular Docking. Metabolic Brain Disease, 2022, 37, 1071-1094.	1.4	11
563	Chimeric Structures in Mental Illnessesâ€”â€œMagicâ€•Molecules Specified for Complex Disorders. International Journal of Molecular Sciences, 2022, 23, 3739.	1.8	4
564	Antidepressant psychopharmacology: is inflammation a future target?. International Clinical Psychopharmacology, 2022, 37, 79-81.	0.9	17
565	A possible causal involvement of neuroinflammatory, purinergic P2X7 receptors in psychiatric disorders. Current Neuropharmacology, 2022, 20, .	1.4	4
566	Developing symptom clusters: linking inflammatory biomarkers to depressive symptom profiles. Translational Psychiatry, 2022, 12, 133.	2.4	10
567	A new perspective on depression and neuroinflammation: Non-coding RNA. Journal of Psychiatric Research, 2022, 148, 293-306.	1.5	17
568	Are sick people really more impulsive?: Investigating inflammation-driven impulsivity. Psychoneuroendocrinology, 2022, 141, 105763.	1.3	2
569	Associations between heart rate variability, peripheral inflammatory markers and major depressive disorder. Journal of Affective Disorders, 2022, 304, 93-101.	2.0	4
570	Inflammation at the crossroads of COVID-19, cognitive deficits and depression. Neuropharmacology, 2022, 209, 109023.	2.0	38
571	Knockdown of FSTL1 inhibits microglia activation and alleviates depressive-like symptoms through modulating TLR4/MyD88/NF-Î°B pathway in CUMS mice. Experimental Neurology, 2022, 353, 114060.	2.0	5

#	Article	IF	Citations
572	Clinical Implications of Cancer Related Inflammation and Depression: A Critical Review. Clinical Practice and Epidemiology in Mental Health, 2021, 17, 287-294.	0.6	6
573	Update on Statin Treatment in Patients with Neuropsychiatric Disorders. Life, 2021, 11, 1365.	1.1	16
574	Mechanisms underlying antidepressant effect of transcutaneous auricular vagus nerve stimulation on CUMS model rats based on hippocampal Î±7nAchR/NF-Î²B signal pathway. Journal of Neuroinflammation, 2021, 18, 291.	3.1	35
575	Cancerâ€related inflammation and depressive symptoms: Systematic review and metaâ€analysis. Cancer, 2022, 128, 2504-2519.	2.0	16
576	Behavioral and Cognitive Consequences of Obesity in Parents and Offspring in Female and Male Rats: Implications of Neuroinflammation and Neuromodulation. Molecular Neurobiology, 2022, 59, 3947-3968.	1.9	5
577	The NLRP3 Inflammasome in Stress Response: Another Target for the Promiscuous Cannabidiol. Current Neuropharmacology, 2023, 21, 284-308.	1.4	5
581	Depression in patients with ankylosing spondylitis. Rheumatology & Autoimmunity, 2022, 2, 69-75.	0.3	4
582	Comedications, underlying comorbidity status and its influence on inflammatory status and depression risk. Brain, Behavior, and Immunity, 2022, 104, 219.	2.0	1
583	Younger women are more susceptible to inflammation: A longitudinal examination of the role of aging in inflammation and depressive symptoms. Journal of Affective Disorders, 2022, 310, 328-336.	2.0	2
584	Effectiveness of microplastics removal in wastewater treatment plants: A critical analysis of wastewater treatment processes. Journal of Environmental Chemical Engineering, 2022, 10, 107831.	3.3	12
585	Repetitive transcranial magnetic stimulation exerts anti-inflammatory effects via modulating glial activation in mice with chronic unpredictable mild stress-induced depression. International Immunopharmacology, 2022, 109, 108788.	1.7	13
586	Associations between Autoimmunity and Depression: Serum IL-6 and IL-17 Have Directly Impact on the HAMD Scores in Patients with First-Episode Depressive Disorder. Journal of Immunology Research, 2022, 2022, 1-6.	0.9	11
587	Immunoinflammatory processes: Overlapping mechanisms between obesity and eating disorders?. Neuroscience and Biobehavioral Reviews, 2022, 138, 104688.	2.9	8
588	Obesity and the Brain. International Journal of Molecular Sciences, 2022, 23, 6145.	1.8	8
589	Neuroinflammation in HIV-associated depression: evidence and future perspectives. Molecular Psychiatry, 2022, 27, 3619-3632.	4.1	16
590	Pathophysiology of SARS-CoV2 Mediated Depression, Therapeutics and Consequences: A Comprehensive Narrative. Mini-Reviews in Medicinal Chemistry, 2022, 22, .	1.1	0
591	Microglial Inflammatory-Metabolic Pathways and Their Potential Therapeutic Implication in Major Depressive Disorder. Frontiers in Psychiatry, 0, 13, .	1.3	27
592	Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression. Journal of Neuroinflammation, 2022, 19, .	3.1	119

#	Article	IF	Citations
593	Obesity-Related Chronic Kidney Disease: Principal Mechanisms and New Approaches in Nutritional Management. Frontiers in Nutrition, 0, 9, .	1.6	23
594	The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation. Brain, Behavior, & Immunity - Health, 2022, 23, 100480.	1.3	1
595	Anxiety-like behavior and microglial activation in the amygdala after acute neuroinflammation induced by microbial neuraminidase. Scientific Reports, 2022, 12, .	1.6	6
596	Distinct proteomic profiles in prefrontal subareas of elderly major depressive disorder and bipolar disorder patients. Translational Psychiatry, 2022, 12, .	2.4	6
597	Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing. Pharmaceuticals, 2022, 15, 827.	1.7	23
598	Ferulic acid: An extraordinarily neuroprotective phenolic acid with anti-depressive properties. Phytomedicine, 2022, 105, 154355.	2.3	14
599	Networks of inflammation, depression, and cognition in aging males and females. Aging Clinical and Experimental Research, 2022, 34, 2387-2398.	1.4	9
600	The role of immunomodulators in treatment-resistant depression: case studies. Cell Death Discovery, 2022, 8, .	2.0	15
601	Testing Bidirectional, Longitudinal Associations Between Disturbed Sleep and Depressive Symptoms in Children and Adolescents Using Cross-Lagged Models. JAMA Network Open, 2022, 5, e2227119.	2.8	5
602	Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Poststroke Depression: A Systematic Review and Meta-Analysis. Disease Markers, 2022, 2022, 1-10.	0.6	6
603	Perspectives on the complex links between depression and dementia. Frontiers in Aging Neuroscience, 0, 14, .	1.7	10
604	The role of the immune system in posttraumatic stress disorder. Translational Psychiatry, 2022, 12, .	2.4	33
605	Severe psychiatric disorders and general medical comorbidities: inflammation-related mechanisms and therapeutic opportunities. Clinical Science, 2022, 136, 1257-1280.	1.8	2
606	Origin of Sex-Biased Mental Disorders: Do Males and Females Experience Different Selective Regimes?. Journal of Molecular Evolution, 2022, 90, 401-417.	0.8	2
607	Association between neutrophil to lymphocyte ratio and depression among US adults: From a large population-based cross-sectional study. Journal of Psychosomatic Research, 2022, 162, 111041.	1.2	5
608	Non-Invasive Brain Stimulation Effects on Biomarkers of Tryptophan Metabolism: A Scoping Review and Meta-Analysis. International Journal of Molecular Sciences, 2022, 23, 9692.	1.8	2
609	A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder. Trials, 2022, 23, .	0.7	2
610	Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing. Cells, 2022, 11, 3031.	1.8	8

#	Article	IF	Citations
612	Study protocol for a phase II, double-blind, randomised controlled trial of cannabidiol (CBD) compared with placebo for reduction of brain neuroinflammation in adults with chronic low back pain. BMJ Open, 2022, 12, e063613.	0.8	2
613	Metformin is Protective Against the Development of Mood Disorders. Pharmacopsychiatry, 2023, 56, 25-31.	1.7	2
614	Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression. JAMA Network Open, 2022, 5, e2230367.	2.8	20
615	Mapping the structure of depression biomarker research: A bibliometric analysis. Frontiers in Psychiatry, 0, 13, .	1.3	2
616	Is depression the missing link between inflammatory mediators and cancer?. , 2022, 240, 108293.		11
617	Current Perspectives on Pharmacological and Non-Pharmacological Interventions for the Inflammatory Mechanism of Unipolar Depression. Brain Sciences, 2022, 12, 1403.	1.1	8
618	Involvement of the IL-6 Signaling Pathway in the Anti-Anhedonic Effect of the Antidepressant Agomelatine in the Chronic Mild Stress Model of Depression. International Journal of Molecular Sciences, 2022, 23, 12453.	1.8	3
619	Targeting inflammation: a potential approach for the treatment of depression. Metabolic Brain Disease, 2023, 38, 45-59.	1.4	17
620	The Missing Piece? A Case for Microgliaâ€™s Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics. Neurochemical Research, 2023, 48, 1129-1166.	1.6	8
621	Attenuation of the levels of pro-inflammatory cytokines prevents depressive-like behavior during ethanol withdrawal in mice. Brain Research Bulletin, 2022, 191, 9-19.	1.4	5
622	Neurobiological Principles: Psycho-Neuro-Immuno-Endocrinology. , 2022, , 25-63.		0
623	Mechanistic insights into the role of plant polyphenols and their nano-formulations in the management of depression. Frontiers in Pharmacology, 0, 13, .	1.6	8
624	Neurobiological Mechanisms Of Depression Following Traumatic Brain Injury. Brain Injury, 2023, 37, 24-33.	0.6	5
625	Sex differences in a double-blind randomized clinical trial with minocycline in treatment-resistant depressed patients: CRP and IL-6 as sex-specific predictors of treatment response. Brain, Behavior, & Immunity - Health, 2022, 26, 100561.	1.3	3
626	Major depression and the biological hallmarks of aging. Ageing Research Reviews, 2023, 83, 101805.	5.0	13
627	Exercise effect on the gut microbiota in young adolescents with subthreshold depression: A randomized psychoeducation-controlled Trial. Psychiatry Research, 2023, 319, 115005.	1.7	9
628	C-reactive protein levels and depression in older and younger adults - A study of 19,947 individuals. The TromsÃ¸ study. Brain, Behavior, & Immunity - Health, 2023, 27, 100571.	1.3	0
629	Ketamine, benzoate, and sarcosine for treating depression. Neuropharmacology, 2023, 223, 109351.	2.0	5

#	Article	IF	Citations
630	Comparative efficacy, acceptability, and tolerability of adjunctive anti-inflammatory agents on bipolar disorder: A systemic review and network meta-analysis. Asian Journal of Psychiatry, 2023, 80, 103394.	0.9	1
631	Depression, Anxiety, and Quality of Life in Patients Treated with Single Infusion Tocilizumab for COVID-19: A Follow-up, Controlled Study. Indian Journal of Psychological Medicine, 2023, 45, 47-52.	0.6	3
632	A Novel Anti-Inflammatory Formulation Comprising Celecoxib and Cannabidiol Exerts Antidepressant and Anxiolytic Effects. Cannabis and Cannabinoid Research, 0, , .	1.5	1
633	Practical applications of grounding to support health. Biomedical Journal, 2023, 46, 41-47.	1.4	3
634	Dissecting the molecular mechanisms underlying the antidepressant activities of herbal medicines through the comprehensive review of the recent literatures. Frontiers in Psychiatry, 0, 13, .	1.3	0
635	Immune cell composition in unipolar depression: a comprehensive systematic review and meta-analysis. Molecular Psychiatry, 2023, 28, 391-401.	4.1	10
638	Anti-Inflammatory Treatment Efficacy in Major Depressive Disorder: A Systematic Review of Meta-Analyses. Neuropsychiatric Disease and Treatment, 0, Volume 19, 1-25.	1.0	11
640	Depressive Disorders. , 2022, , .		0
642	Peripheral blood cellular immunophenotype in depression: a systematic review and meta-analysis. Molecular Psychiatry, 2023, 28, 1004-1019.	4.1	16
643	Microbiotaâ€“gutâ€“brain axis mechanisms in the complex network of bipolar disorders: potential clinical implications and translational opportunities. Molecular Psychiatry, 2023, 28, 2645-2673.	4.1	22
644	Integrating mechanistic-based and classification-based concepts into perioperative pain management: an educational guide for acute pain physicians. Regional Anesthesia and Pain Medicine, 0, , rapm-2022-104203.	1.1	0
645	Neurotoxicity in Depression. , 2022, , 2085-2114.		0
646	Why Are Some People with Lower Urinary Tract Symptoms (LUTS) Depressed? New Evidence That Peripheral Inflammation in the Bladder Causes Central Inflammation and Mood Disorders. International Journal of Molecular Sciences, 2023, 24, 2821.	1.8	5
647	Association of systemic inflammatory biomarkers with depression risk: Results from National Health and Nutrition Examination Survey 2005â€“2018 analyses. Frontiers in Psychiatry, 0, 14, .	1.3	7
648	Melanin-like polydopamine nanoparticles mediating anti-inflammatory and rescuing synaptic loss for inflammatory depression therapy. Journal of Nanobiotechnology, 2023, 21, .	4.2	11
649	Serum cytokine variations among inpatients with major depression, bipolar disorder, and schizophrenia versus healthy controls: a prospective â€˜true-to-lifeâ€™ study. Therapeutic Advances in Psychopharmacology, 2023, 13, 204512532211354.	1.2	1
650	Early Life Stress, Neuroinflammation, and Psychiatric Illness of Adulthood. Advances in Experimental Medicine and Biology, 2023, , 105-134.	0.8	2
651	C-Reactive Protein (CRP): A Potent Inflammation Biomarker in Psychiatric Disorders. Advances in Experimental Medicine and Biology, 2023, , 135-160.	0.8	1

#	Article	IF	Citations
652	Anti-Inflammatory Effect of Traditional Chinese Medicine on the Concept of Mind-Body Interface. Advances in Experimental Medicine and Biology, 2023, , 435-458.	0.8	2
653	The Melanocortin System: A Promising Target for the Development of New Antidepressant Drugs. International Journal of Molecular Sciences, 2023, 24, 6664.	1.8	2
654	The human P2X7 receptor alters microglial morphology and cytokine secretion following immunomodulation. Frontiers in Pharmacology, 0, 14, .	1.6	4
655	Building an infrastructure to support the development, conduct, and reporting of informative clinical studies: The Rockefeller University experience. Journal of Clinical and Translational Science, 2023, 7, .	0.3	1
656	Sickness behaviour and depression: An updated model of peripheral-central immunity interactions. Brain, Behavior, and Immunity, 2023, 111, 202-210.	2.0	11
657	Prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Incidence of Depression Among Older Cancer Survivors With Osteoarthritis: A Machine Learning Analysis. Cancer Informatics, 2023, 22, 117693512311651.	0.9	1
658	Reduced numbers of naÃ¯ve CD4Â+ÂT cells and an altered CD4/CD8 balance in depressed common variable immune deficiency (CVID) patients. Is thymosin-Î±1 a possible treatment?. International Immunopharmacology, 2023, 119, 110168.	1.7	1
674	Biological factors influencing depression in later life: role of aging processes and treatment implications. Translational Psychiatry, 2023, 13, .	2.4	7
681	Purinergic Signaling in Depression. , 2023, , 129-190.		0
684	Stress, aging, and inflammation. , 2024, , 99-118.		0
688	Psychoneuroimmunology in Pula: A Hot Topic with a Long Past. , 2023, , 141-150.		0
694	Influence of Vagus Nerve Stimulation on Mood and Associated Disorders. Neuromethods, 2024, , 131-155.	0.2	0
711	Anti-inflammatory Drugs in the Treatment of Depression. Current Topics in Behavioral Neurosciences, 2023, , .	0.8	0
715	Genetic evidence for causal effects of immune dysfunction in psychiatric disorders: where are we?. Translational Psychiatry, 2024, 14, .	2.4	0